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ABSTRACT
MBD1, a member of the methyl-CpG-binding
domain family of proteins, has been reported to
repress transcription of methylated and
unmethylated promoters. As some MBD1 isoforms
contain two DNA-binding domains—an MBD, which
recognizes methylated DNA; and a CXXC3 zinc
finger, which binds unmethylated CpG—it is
unclear whether these two domains function inde-
pendently of each other or if they cooperate in
facilitating recruitment of MBD1 to particular
genomic loci. In this report we investigate DNA-
binding specificity of MBD and CXXC3 domains
in vitro and in vivo. We find that the methyl-CpG-
binding domain of MBD1 binds more efficiently to
methylated DNA within a specific sequence
context. We identify genes that are targeted by
MBD1 in human cells and demonstrate that a func-
tional MBD domain is necessary and sufficient for
recruitment of MBD1 to specific sites at these loci,
while DNA binding by the CXXC3 motif is largely
dispensable. In summary, the binding preferences
of MBD1, although dependent upon the presence
of methylated DNA, are clearly distinct from
those of other methyl-CpG-binding proteins, MBD2
and MeCP2.
INTRODUCTION
DNA methylation at CpG dinucleotides is an abundant
modiﬁcation in vertebrate and plant genomes (1,2).
Generally, DNA methylation associates with formation
of heterochromatin in the genome and, when detected
near transcription start sites (TSS) of genes, leads to
stable transcriptional silencing (1,3). Although  62% of
human gene promoters are CpG-rich and are usually free
of DNA methylation, a fraction of these is methylated in
diﬀerentiated tissues and a large number of promoters can
be aberrantly methylated in human cancers (4–7). In
addition, a signiﬁcant proportion of CpG-poor and inter-
mediate CpG-density promoters, which account for
 38% of human protein coding genes, are usually
methylated in normal human somatic cells (7).
Expression analyses of mouse and human cells deﬁcient
for the maintenance DNA methyltransferase enzyme
Dnmt1 have identiﬁed a large number of missexpressed
transcripts, suggesting that DNA methylation is essential
for the maintenance of a transcriptionally inactive state of
many genes (8,9).
Transcriptional silencing by DNA methylation operates
in part via proteins that bind to methylated DNA and
recruit co-repressor complexes containing histone
deacetylases and histone methylase activities (10). Three
families of proteins that bind to methylated DNA have
been identiﬁed so far. These include: the MBD domain
family; Kaiso and Kaiso-like proteins and the SRA
domain proteins (11). The MBD family consists of
MBD1, MBD2, MBD3, MBD4 and MeCP2 (12). Three
of these proteins, MBD1, MBD2 and MeCP2, function as
methylation-dependent transcriptional repressors
(10,13–15). Mice null for these three proteins are viable
and, with the exception of Mecp2-deﬁcient animals,
display relatively mild, but distinct, phenotypes (16–20).
This is in stark contrast to mice deﬁcient in DNA
methyltransferase enzymes, which die early in develop-
ment (21,22). As MBD proteins are ubiquitously ex-
pressed in all somatic tissues, although at varying levels,
functional redundancy between MBD family members
and, perhaps, with other methyl-CpG-binding proteins
has been the most common explanation for the mild
phenotypes of Mbd1 and Mbd2 null animals.
This hypothesis is supported in part by observations
that in human cancer cell lines several MBD proteins
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However, even in cancer cells a proportion of methylated
promoters are occupied by a single MBD protein (23,25).
Chromatin immunoprecipitation (ChIP)-and-clone experi-
ments have shown that shared occupancy of methylated
sites by several MBD proteins is rarely observed in
primary human lung ﬁbroblasts (26). Moreover, MeCP2
was unable to colonize methylated sites vacated after
MBD2 knock down, while MBD2 could migrate into
about half of the binding sites generated by knocking
down MeCP2 (26). These experiments indicate that
MeCP2 has binding preferences distinct from these of
MBD2 and subsequently it was found that high aﬃnity
binding of MeCP2 to methylated DNA requires a run of
four or more A/T bases adjacent to a methylated CpG
(26). Whether MBD1 can recognize methylated DNA in
some preferred sequence context is currently unknown.
MBD1 is the largest protein of the MBD family. It co-
operates with a histone H3K9 methylase SETDB1 and its
cofactor AM/MCAF to repress transcription (27,28). In
addition to an MBD domain, MBD1 contains
CXXC-type zinc ﬁngers, and a transcriptional repression
domain (TRD) located at the C-terminus (15,29). Several
MBD1 isoforms with either two or three CXXC motifs
have been identiﬁed in human and mouse cells (30,31).
The third CXXC motif, CXXC3, is present in three of
the ﬁve isoforms of human MBD1 and is highly homolo-
gous to the cysteine-rich zinc ﬁngers of histone H3K4
methylase MLL, DNA-binding protein CGBP and main-
tenance DNA methyltransferase DNMT1 (29,31,32). The
CXXC3 domain of mouse Mbd1 can bind unmethylated
DNA in vitro and localizes to pericentric heterochromatin
when expressed in cells that lack Dnmt1 (31). NMR and
band-shift studies indicate that CXXC of MLL binds to a
single CpG pair via amino acids located in an extended
loop formed within a crescent-like structure stabilized by
eight cysteine residues coordinating two zinc atoms (32).
The other two CXXC motifs of MBD1, although similar
to CXXC3, diﬀer signiﬁcantly in key amino acids within
the positively charged DNA-binding loop and do not bind
to DNA in vitro (31). Consistent with the presence of two
DNA-binding domains, it has been reported that MBD1
isoforms carrying CXXC3 repress transcription from
methylated and unmethylated promoters in transient
reporter assays (31,33). However, it remains unclear
whether cooperation between the MBD and CXXC3
domains of MBD1 is essential for recruitment of MBD1
to speciﬁc genomic loci in vivo.
In this report we investigate in detail the DNA-binding
preferences and relative contribution of MBD and
CXXC3 domains to stable binding of MBD1 to DNA
in vitro and in vivo. We show that the MBD domain of
MBD1 recognizes methylated CpGs within TCGCA and
TGCGCA sequence context more eﬃciently than any
other sequence we tested, while the CXXC3 motif
requires a single unmethylated CpG and displays no de-
tectable preference for particular ﬂanking nucleotides.
Using a transactivator fusion approach we identify
speciﬁc target genes for MBD1 in several human cell
lines and ﬁnd that they often contain unmethylated
CpG-rich promoters and methylated high aﬃnity
MBD1-binding sites located in the vicinity of the TSS.
We also demonstrate that stable binding of MBD1 to
DNA in vivo, including at MBD1 targeted loci, requires
a functional MBD domain but not DNA binding by
CXXC3. Point mutations in CXXC3 that completely
abolish binding to unmethylated DNA in vitro do not
disrupt the recruitment of MBD1 to target genes. Taken
together, this indicates that MBD1 functions primarily as
a methyl-CpG-binding protein with a preference for
speciﬁc methylated sites. Our data also suggest that
MBD family proteins have evolved towards more
speciﬁc recognition of methylated DNA by their MBD
domains leading to silencing of a restricted subset of
target genes by each of these proteins.
MATERIALS AND METHODS
Recombinant proteins
For recombinant protein expression and puriﬁcation, all
MBD1 fragments were cloned into EcoRI and XhoI sites
of pGEX-4T-1. MBD1 deletions corresponding to
residues 1–161 or 1–125 were used for methylated
DNA-binding assays. For CXXC3 DNA-binding experi-
ments, an MBD1 fragment corresponding to amino acids
252–344, was used. The GST-CXXC3-His construct was
generated by ligating a double-stranded oligonucleotide
encoding an hexahistidine tag into XhoI and NotI sites
in the PGEX-4T-1 plasmid. pGEX-MeCP2 1–162 has
been described (34). All recombinant proteins were
produced in Escherichia coli BL21 strain according to
standard procedures. GST fusion proteins were puriﬁed
using glutathione sepharose (GE Healthcare), eluted
with reduced glutathione and buﬀer was exchanged to
50mM Tris–HCl pH 7.5, 10% glycerol, 150mM NaCl,
1mM DTT using NAP-10 columns (GE Healthcare).
Puriﬁed proteins were concentrated using Millipore ﬁlter
device and stored at  80 C. The GST-CXXC3 fusion
protein was cleaved with thrombin (GE Healthcare)
prior to use in bandshift assays.
SELEX
Methyl-SELEX was performed essentially as described
(26). The following sequence: 50ACCAGGAAGCTTCT
GTATGTAGATCTG-N(16)-GCGC-N(16)-GAGATCT
CCTAAGACTTCTAGATCCC30 was used to generate
the starting methyl SELEX library by annealing a
reverse primer 50GGGATCTAGAAGTCTTAGGAGAT
CTC30 followed by extension by Klenow polymerase. The
gel puriﬁed double-stranded DNA fragments were
methylated with M.HhaI methyltransferase, end labelled
with [g-
32P] dATP by T4 poly nucleotide kinase (PNK)
and used in an electrophoretic mobility shift assay
(EMSA) reaction with increasing amount of
GST-MBD1 1–161 (10, 50 and 150nM) in the presence
of 1mg of poly(dG–dC) poly(dG–dC) (GE Healthcare).
Shifted bands were cut out, boiled for 10min and the
eluted material was used for PCR ampliﬁcation using
the following primers: F 50ACCAGGAAGCTTCTGTA
TGATGATCTG30 and R 50GGGATCTAGAAGTCTT
AGGAGATCTC30. The resulting PCR product was
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CXXC3 domain was performed using the following oligo-
nucleotide: ACCAGGAAGCTTGTTTCCCAGTCACT
ACA-N(5)-CG-N(5)-AGTCATAGCTGG TTCCTGCC
TAAGACTTCTAGATCCC. GST-CXXC3-His fusion
protein was cleaved with thrombin and immobilized on
magnetic Ni
2+-Beads (Dynal). SELEX assay was the per-
formed as described (35). After the last round of selection,
PCR products were digested with HindIII and XbaI then
cloned in pBluescript for sequencing.
EMSA
Oligonucleotides used for EMSA were synthesized in their
methylated or unmethylated forms, and correspond to the
sequence ACATGCCTCATGCCGGACTTAACTGCA
GCT with the indicated substitutions. Complementary
probes were annealed, puriﬁed on polyacrylamide gels
and end labelled with [g-
32P] dATP by T4 PNK. Puriﬁed
proteins were mixed at the indicated concentrations with
radiolabelled probes in EMSA-binding buﬀer (20mM
Hepes pH 7.9, 150mM KCL, 5% glycerol, 0.1% Triton
X-100, 0.2mM EDTA, 2mM DTT, 100mg/ml BSA
including 250ng poly(dA–dT) poly(dA–dT) or 150nG
poly(dI–dC) poly(dI–dC). After 10min of incubation at
room temperature, the reaction mixtures were loaded onto
6 or 8% polyacrylamide  1 Tris–glycine–EDTA gels and
run for 2h, 180V at 4 C. Gels were dried exposed to a
PhosphorImager screen (Molecular Dynamics) or auto-
radiographed. To determine the relative KD of MBD
binding to diﬀerent probes, poly(dA–dT) poly(dA–dT)
was reduced to 100ng. Radioactivity was quantiﬁed by
PhosphorImager from at least three independent experi-
ments and the bound fraction (bound DNA/[bound DNA
+free DNA]) was calculated for each protein concentra-
tion. Binding curves were ﬁtted using Sigma Plot Systat
Software.
Plasmids, cells and transient transfections
To generate MBD-VP16 expression plasmids sequences
containing amino acids 1–314 of MBD1 (PCM1
variant), 1–205 of MeCP2 and 1–214 of MBD2 were
PCR ampliﬁed and cloned into NotI and EcoRI sites of
pCMV-Tag4 (Promega). VP16 activation domain was
PCR ampliﬁed from pTET-ON plasmid (Clontech) and
cloned into EcoRI and XhoI sites between and in frame
with MBD and C-terminal FLAG tag. MBD1 point mu-
tations were introduced into MBD1
PCM1-VP16 by muta-
genic PCR. MBD1 shRNA and non-silencing control
plasmids were purchased from SABioscience. MBD2
shRNA and non-silencing control were purchased from
Open Biosystems. The plasmids were transfected into
HeLa, NCI-H226, HCT116, HCT116 DNMT3B KO
and DNMT1/DNMT3B DKO cells by electroporation
using Nucleofection device and transfection reagents
(Amaxa Biosystems). In all large scale experiments 5mg
of plasmid DNA was used for 1.3 10
6 cells.
Western blots
Cells transfected with plasmids expressing wild-type or
mutated MBD-VP16 fusions were collected 48h
post-transfection. Two-third of each sample was used for
RNA extraction and one-third was used to prepare
nuclear extracts using modiﬁed Dignam protocol (27).
Nuclear extracts (25–40mg) were run on 10% SDS–
PAGE gels and the fusion proteins and HDAC1 control
protein were detected by anti-FLAG M2 (Sigma) and
anti-HDAC1 sc-7872 (Santa Cruz Biotechnology)
antibodies followed by secondary IRDye 800CW donkey
anti-mouse, IRDye 680 donkey anti-rabbit antibodies
(LiCor Biosciences). Images were acquired on LiCor
Odyssey Infrared Imager (LiCor Biosciences) and
quantiﬁed by Odyssey V3.0 Software.
RNA extraction, semi-quantitative and RT-qPCR
RNA was extracted using Trizol reagent (Invitrogen) ac-
cording to manufacturer’s instructions. cDNA was
prepared from 4mg of total RNA using poly-dT primer
and SuperScriptII reverse transcriptase (Invitrogen) ac-
cording to standard protocols. For semi-quantitative
RT-PCR 60-, 30-, 15- and 7.5-fold dilutions of each
cDNA sample was ampliﬁed with control primers for
gamma-Actin and primers speciﬁc for HBA1, HBA2,
NGFR, RND2 and ASPP2. RT-qPCR reactions (25ml)
were performed in quadruplicate (iCycler, Bio-Rad)
using 2X SYBR Green Supermix (Bio-Rad
Laboratories) and quantiﬁed by Bio-Rad iCylcer iQ
system software. Normalization and analysis for each
target gene were carried out using ACTB as a reference
gene, according to standard methods using the following
equation: Ratio=(Etarget)
Ct (control–target)/
(Eref)
Ct (control–sample) (36). Primer sequences are available
on request.
Microarray experiments and data analyses
Each experiment was carried out in three biological
replicas on human spotted cDNA arrays (CRUK22K,
Cancer Research UK), with cDNA from untransfected
cells and from cells transfected with either
pCMV-MBD1-VP16-Tag4 or the double mutant R22A/
2CA control. Each experiment included at least one dye
swap. The cDNA was directly labelled with either
[Cy3]dCTP or [Cy5]dCTP (GE Healthcare, UK) by
reverse transcription of 80–100mg of total RNA. Reverse
transcription was performed overnight according to
standard protocols, using an anchored poly(dT) oligo
primer and SuperScriptII reverse transcriptase
(Invitrogen). After labelling, RNA was hydrolysed at
65 C for 200 in basic conditions, and the labelled cDNA
was puriﬁed through a QiaQuick spin column (Qiagen).
The incorporation of labelled nucleotides into cDNA was
assessed with a Nanodrop 1000 spectrophotometer
(Thermo Scientiﬁc) at 550 and 650nm wave length, re-
spectively. Hybridizations were performed at 45 C for
 20h in hybridization buﬀer containing 5  SSC, 6 
Denhart’s solution, 60mM Tris–HCl pH 8 and 48%
deionized formamide. After hybridization and subsequent
washing, the arrays were scanned and quantiﬁed using a
Genepix 4200AL scanner (Molecular Devices). Raw data
were background corrected using the ‘Normexp’ algo-
rithm, loess normalized using the Limma package (37)
4622 Nucleic Acids Research, 2010,Vol.38, No. 14from the BioConductor project and analysed in R envir-
onment, using Limma and standard R/BioConductor
tools (38). To identify possible targets for the
MBD1-VP16 fusion protein, we subtracted the genes
activated by the double mutant control from the ones
activated in the MBD1-VP16 sample, and kept those
with values log2(transfected/untransfected) >1.5 with a
0.05 false discovery rate (FDR) cut oﬀ. Microarray data
are submitted to ArrayExpress, accession number:
E-MTAB-103.
Bisulphite DNA sequencing
Genomic DNA was phenol–chloroform extracted from
cultured cells after RNAse A and proteinase K digestion.
Bisulphite treatment of genomic DNA was carried out as
described (39), and prepared for sequencing as outlined in
ref. (40). Genomic DNA (2mg) was treated with sodium
bisulphite and precipitated after the desulphonation step.
The samples were resuspended in 1 Tris–EDTA buﬀer
for subsequent PCR and sequencing reactions. Colony
PCRs were performed, clones of the correct size were
sequenced and sequences were analysed using BiQ
Analyser (41). A list of primers used for bisulphite
sequencing of HBA, NGFR and RND2 promoters can
be found in the Supplementary Data.
ChIP
ChIP experiments were performed essentially as described
(42). Typically chromatin from 3 10
6 cells and 2–5mg
of antibody were used for each IP. The antibodies used
were anti-VP16AD, sc-7546 (Santa Cruz Biotechnology),
anti-MBD1 sc-10751 (Santa Cruz Biotechnology), anti-H3
K9/K14ac 06–599 (Millipore). 1/100 of DNA puriﬁed
from ChIP was used in each 20ml qPCR reaction. All
qPCRs were performed in triplicates on three independent
ChIP samples. Primer sequences are available on request.
RESULTS
Recognition of methylated and unmethylated CpGs by
DNA-binding domains of MBD1
To investigate in detail DNA-binding properties of
MBD1, we generated recombinant GST-tagged proteins
that correspond to the MBD and the CXXC3 domains,
respectively, (Supplementary Figure S1) and used them in
EMSA experiments. We ﬁrst investigated whether the ef-
ﬁciency of complex formation of these domains with
double-stranded DNA probes is aﬀected by the bases im-
mediately adjacent to the CpG dinucleotide. To do so, we
performed base substitution scanning mutagenesis at pos-
itions  1 and +1 relative to the methylated or the
unmethylated CpG. Interestingly, when we tested the
MBD domain of MBD1 against probes containing C, G,
T or A nucleotides at positions either  1 or+1 relative to
methylated CpG, we observed a marked preference of
MBD domain for T at position  1 and C at position+1
(Figure 1A). When these two ﬂanking bases were
combined into a probe containing TC
MGC sequence, we
detected an additive eﬀect on MBD binding as evident by
the increased band-shift eﬃciency compared to probes
containing either TC
MGG or CC
MGC (Supplementary
Figure S2A). In similar experiments with unmethylated
DNA, the CXXC3 domain of MBD1 bound all probes
with approximately equal eﬃciency (Figure 1B). Thus
the base pairs ﬂanking methylated CpG aﬀect signiﬁcantly
the aﬃnity of the MBD domain for methylated DNA, but
have little if any eﬀect on binding eﬃciency of the CXXC3
zinc ﬁnger to unmethylated CpG.
In parallel with base substitution mutagenesis, we also
undertook in vitro binding site selection (SELEX) using
pools of DNA fragments containing methylated
(methyl-SELEX) (26) or unmethylated CpGs to identify
potential additional sequence requirements for the MBD
and CXXC3 domains, respectively. The sequences re-
covered from the SELEX with CXXC3 enriched only
for additional CpG pairs, further indicating that this
domain has no extended recognition sequence (data not
shown). In contrast, the methyl-SELEX assay performed
with the MBD domain of MBD1 on a pool of
double-stranded fragments containing a ﬁxed GCGC
sequence methylated with HhaI methylase produced a dif-
ferent outcome. After eight cycles of binding and ampliﬁ-
cation, the fragments recovered from the EMSA gels were
cloned and sequenced. Interestingly, 82 out of 87
fragments contained one or more (97 in total) palindromic
TGCGCA sequences (Supplementary Figure S3). In
addition to TGCGCA sites, we also observed an expan-
sion of GCGC sequences in the selected pool
(Supplementary Figure S3). Thus the MBD domain
of MBD1 was able to select simultaneously for a unique
TGCGCA site containing a single methylated CG as well
as a multiple methylated CGs within the extended GCGC
sequence. As most methylated CpGs in the genome are
not located within GC-rich stretches of DNA, we
further focused on MBD selected sequences containing a
single CG.
A subset of fragments derived from the methyl-SELEX
assay with the MBD of MBD1 was further tested in inde-
pendent band-shift experiments. Probes containing the
methyl-SELEX-enriched TGC
MGCA motif were as eﬃ-
cient in supporting complex formation with the MBD
domain of MBD1 as probes with TC
MGC derived from
base substitution mutagenesis experiments (Figure 1C). As
the GCGC core sequence was imposed by the use of HhaI
methylase, it appeared that the only two selected bases in
the enriched TGC
MGCA motif were T and A positioned
at  2 and +2, respectively, relative to methylated CpG.
Combining the information derived from base substitu-
tion scanning mutagenesis and the methyl-SELEX, we
predicted and veriﬁed experimentally that TTC
MGCA
constitutes a high aﬃnity binding site for the MBD of
MBD1 (Figure 1D). However, T at  2 and A at +2 did
not contribute equally, as the MBD domain of MBD1
displayed signiﬁcantly reduced binding when A at +2
was substituted to C, but not when T at  2 was
replaced with G (Figure 1D). We conclude that the
identiﬁed palindrome sequence TGC
MGCA reﬂects the
selection of A at position +2 relative to methylated
CpG. As this sequence can be read by the MBD domain
on both DNA strands, this may explain why it was
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Figure 1. Binding speciﬁcity of MBD and CXXC3 domains of MBD1 in vitro. (A) EMSA combined with base substitution scanning mutagenesis of
nucleotides adjacent to methylated CpG detect preferential binding of MBD domain to probes with T in position  1 and C in position +1. Lanes
labelled with ‘ ’ contain no protein. The triangle indicates increasing concentrations of MBD (75 and 200nM). All probes used in these experiments
happen to contain an A at position+2 from the CG. Therefore MBD1 binds seemingly identical probes such as T
MCGG and C
MCGA or G
MCGG
and C
MCGC with diﬀerent eﬃciency. (B) The CXXC3 domain binds with similar eﬃciency to all unmethylated probes containing a CG pair
independently of the sequence context, but does not bind to methylated probes. Lanes labelled with ‘ ’ contain no protein. The triangle indicates
increasing amounts of CXXC3 (50–200nM). (C) The MBD domain of MBD1 (M1) but not the MBD domain of MeCP2 (Me2) eﬃciently binds
TG
MCGCA sequence enriched in methyl-SELEX experiment and probe containing T
MCGC from base substitution scanning mutagenesis with A at
position +2. 200nM of M1 and Me2 were used in these EMSA experiments. (D) Replacement of A to C at position +2 in T
MCGCA sequence
reduces the aﬃnity of MBD1 MBD domain to methylated probe. Replacement of T at position  2 with G does not aﬀect the eﬃciency of binding.
(E) Relative KD of MBD1 MBD binding to probes containing the optimal (T
MCGCA) or suboptimal methylated binding sites. Note that the MBD
domain binds T
MCGCA probe 3–5-fold more eﬃciently than any other methylated sequence.
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Therefore, the shortest sequence containing a single
methylated CG which supports high aﬃnity binding of
the MBD domain of MBD1 is TC
MGCA followed by
TGC
MGCA. Overall, the aﬃnity of MBD domain to
methylated DNA was 3–5-fold higher when probes con-
taining TC
MGCA were compared to suboptimal se-
quences (Figure 1E and Supplementary Figure S4). Most
importantly, probes that supported high aﬃnity binding
of the MBD domain of MBD1 formed weaker complexes
with the MBD domain of MeCP2, irrespective of whether
they contained an A/T run (Figure 1C and Supplementary
Figure S2B). This indicates that these two MBD domains
recognize methylated DNA within speciﬁc sequence
contexts diﬀerently from each other.
In summary, from these experiments we conclude that
the MBD domain of MBD1 binds more eﬃciently to a
single methylated CpG within TC
MGCA and
TGC
MGCA sequence context while the CXXC3 domain
binds unmethylated CpG and shows no apparent prefer-
ence towards particular base pairs ﬂanking the CpG
dinucleotide.
Point mutations in MBD and CXXC3 domains of MBD1
abolish DNA binding
Potentially, the two DNA-binding domains of MBD1
could either function independently of each other or co-
operate in the recruitment of MBD1 to speciﬁc genomic
loci. To investigate this, we introduced point mutations in
the MBD or CXXC3 domains of MBD1 (Supplementary
Figure S1) and tested in vitro whether they abolish binding
to methylated or unmethylated DNA, respectively. The
solution structure of the MBD domain of MBD1 has
been solved by NMR and shown to consist of four
beta-sheets, an alpha-helix and an extended loop L1
(Figure 2A) (43). Several residues, including arginine
22 (R22) at the base of L1 are involved in binding to
symmetrically methylated CpGs. As shown previously
(31,43) and conﬁrmed by our band-shift experiments, a
replacement of R22 with alanine (R22A) almost complete-
ly abolished binding of the MBD domain to methylated
DNA (Figure 2B). To disrupt binding of the CXXC3 to
DNA, we mutated either both zinc coordinating cysteines
(C289,292A), which should perturb the folding of CXXC3
domain (32), or the conserved lysine residues (K310A,
K312A and K319A) of the DNA-binding loop
(Figure 2A). None of the mutant CXXC3 peptides could
bind eﬃciently to DNA in vitro (Figure 2C and D). Based
on these experiments we designed mutant MBD1 proteins
to investigate the contribution of MBD and CXXC
domains in the recruitment of MBD1 to speciﬁc loci
in vivo.
MBD1-VP16 transactivator fusion targets speciﬁc genes
in HeLa cells
As a strategy to identify genes that are normally silenced
by MBD1, we transfected HeLa cells with plasmid ex-
pressing MBD1-VP16 protein which contains amino
acids 1–341 of MBD1 fused to the strong transactivation
domain of the herpes virus protein VP16 (VP16AD)
followed by a C-terminal FLAG-tag (Figure 3A).
Additionally, we transfected cells with plasmids expressing
amino acids 1–205 of MeCP2 or amino acids 1–214 of
MBD2 also fused to VP16AD-FLAG (Figure 3A). To
control for non-speciﬁc eﬀects resulting from introducing
VP16AD into the cells, we also expressed at comparable
levels a double mutant construct MBD1
R22A/C289,292A-
VP16 (DM-VP16) carrying point mutations in the MBD
and CXXC3 DNA-binding domains. All fusion proteins
expressed equally well when transiently transfected into
HeLa cells or other human cell lines (Figure 3B and C,
Supplementary Figure S6 and data not shown). We
expected the MBD-VP16 fusion proteins to bind at their
endogenous genomic locations and, if such binding occurs
near or at a gene promoter, to activate the adjacent gene
via recruitment of SAGA histone acetyltransferase (HAT)
complex by the VP16AD (44). Thus we predicted that
genes normally silenced by a particular MBD protein
will be activated in this assay.
In order to identify such genes, we extracted RNA from
cells transiently expressing MBD1-VP16 or controls.
cDNAs were synthesized, labelled and hybridized to
microarrays containing probes for  10000 human genes.
Comparison of HeLa cells transfected with MBD1-VP16
to controls expressing DM-VP16 identiﬁed 34 transcripts
that were up-regulated 3–16-fold (Figure 3D, left panel;
and Supplementary Table S1). None of these transcripts
were signiﬁcantly induced by the MBD2-VP16 fusion and
only four responded weakly to the expression of
MeCP2-VP16 (Figure 3D, middle and right panels).
Interestingly, most of the transcripts induced by
MBD1-VP16 in HeLa represented tissue-speciﬁc genes,
which are normally not expressed either in HeLa or in
the normal cervix tissue. We did not detect mRNAs sig-
niﬁcantly down-regulated by MBD1-VP16 or any other
MBD-VP16 fusion proteins (Figure 3D). Experiments per-
formed with HCT116 and H226 cell lines produced similar
results, although most of the transcripts as well as their
numbers were diﬀerent, perhaps reﬂecting cell line-speciﬁc
DNA methylation patterns (Supplementary Table S1 and
data not shown).
To validate independently the microarray results, we
selected three of these genes, HBA, RND2 and NGFR
for further analyses. HBA, haemoglobin alpha, is
transcribed from a pair of almost identical genes, HBA1
and HBA2, which are located on chromosome 16. The
two HBA transcripts diﬀer only in their 30 untranslated
regions, encoded by their third exons. The expression of
HBA is normally restricted to the cells of the erythroid
lineage and is regulated by GATA factors (45,46). RND2
is a small Rho GTPase expressed primarily in brain and
testis. RND2 is essential for migration of diﬀerentiating
neural progenitor cells into the brain cortex (47). NGFR/
p75 (NTR) is a neural growth factor receptor normally
expressed in neurons and weakly in other tissues. The
NGFR and RND2 genes are located in on chromosome
17 (17q21–22 and 17q21, respectively). Additionally, we
examined the expression of p53BP2/ASPP2, which was
previously identiﬁed as a gene silenced by MBD1 in
HeLa (27). When tested by semi-quantitative RT-PCR
or real time RT-qPCR the transcripts for HBA, RND2,
Nucleic Acids Research, 2010,Vol.38, No. 14 4625NGFR and p53BP2 were barely detectable in HeLa and in
control cells transfected with either MBD2-VP16 or
MeCP2-VP16 fusions. However, the same transcripts
were highly up-regulated in MBD1-VP16 transfected
cells (Figure 4A and B). These experiments indicate that
the genes activated by MBD1-VP16 fusion protein are not
targeted by other MBD-VP16 fusions and therefore may
represent speciﬁc targets for MBD1 in HeLa.
Contribution of MBD and CXXC3 domains to binding of
MBD1 at target genes
To investigate further whether the recruitment of MBD1
to speciﬁc loci is guided by DNA-binding preferences of
MBD, CXXC3 or cooperative binding to DNA of both
domains, we expressed in HeLa cells MBD1-VP16
proteins carrying mutations either in the MBD
(R22A-VP16) or in the CXXC3 domain (K310,
319A-VP16; C289A,C292A-VP16) and monitored
whether these proteins were capable of activating
MBD1-VP16 target genes. All mutant proteins expressed
equally well in HeLa cells after transient transfection of
the corresponding plasmids (Figure 3C).
Semi-quantitative or real time RT-qPCR detected a
4–10-fold weaker induction of HBA, RND2 and NGFR
by peptides carrying the MBD mutation (R22A-VP16 and
DM-VP16) compared to ‘wild-type’ MBD1-VP16 (Figure
4C and D). RT-qPCR analyses of six additional tran-
scripts showed similar lack of induction by MBD1
R22A-
VP16 (Supplementary Figure S7). However, cells express-
ing MBD1-VP16 with mutations in DNA-binding lysines
of CXXC3, K310,319A, activated HBA, NGFR and
RND2 at levels comparable to the ‘wild-type’
MBD1-VP16 (Figure 4C and D). Interestingly, mutations
in CXXC3 zinc binding cysteine residues, C289,292A, also
compromised activation of HBA, RND2 and NGFR, sug-
gesting that a misfolded CXXC domain close to VP16AD
may have a general deleterious eﬀect on the overall struc-
ture of the fusion protein (Figure 4C and D). Taken
together, these experiments suggest that in most cases
stable binding to methylated DNA via the MBD domain
is essential for the recruitment of MBD1-VP16 to target
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Figure 2. Mutations in MBD and CXXC3 domains disrupt DNA binding. (A) Schematic representation of PCM1 variant of MBD1. The MBD
domain, CXXC zinc ﬁngers and transcriptional repression domain (TRD) are indicated. The solution structure of the MBD (43) and CXXC3
domains (32) is shown as well as the position of amino acids, which we have mutated, contributing to DNA binding (red) or coordination of zinc
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4626 Nucleic Acids Research, 2010,Vol.38, No. 14genes, while DNA binding by the CXXC3 domain is
largely dispensable. Nevertheless, from these experiments
we could not exclude that the CXXC3 stabilizes the inter-
action of MBD1 with DNA once the MBD domain is
bound.
Alternatively spliced isophorms of human MBD1
include variants 3 and 4, which contain CXXC1 and
CXXC2 domains but lack CXXC3 (30). Variants 1 and
2 carry CXXC1, CXXC2 and CXXC3, while PCM1
contains CXXC2 and CXXC3 (Figure 5A). Aiming to
investigate further whether CXXC3 contributes to
binding of MBD1 at target genes, we compared the
ability of MBD1-VP16 (derived from the PCM1
isoform) and MBD1
Var3-VP16 to activate HBA and
RND2. When we expressed MBD1-VP16 and
MBD1
Var3-VP16 in HeLa cells at comparable levels, we
found that they did not diﬀer signiﬁcantly in their capacity
to activate target genes as detected by RT-qPCR
(Figure 5B and C). These experiments indicate that the
CXXC3 domain is largely dispensable for the recruitment
of MBD1-VP16 to its target genes in HeLa cells.
MBD1-VP16 and endogenous MBD1 bind to high aﬃnity
sites near the RND2 and NGFR promoters
In order to investigate if binding of MBD1-VP16 occurs at
or near NGFR, RND2 and HBA promoters, we ﬁrst
determined their DNA methylation patterns by bisulphite
sequencing. We found that the sequences ﬂanking TSS of
NGFR and HBA genes were not methylated, while the
RND2 promoter was partially methylated at sequences
immediately adjacent to the TSS (Figure 6A and C, and
7A). Notably, TCGCA sequences, which we identiﬁed as
high aﬃnity binding sites for MBD1 (Figure 1), are
present near these promoters: at +801 from the TSS of
NGFR gene and +1315, +2640 and +2746 from the
TSS of RND2 (Figure 5A and C). Four TCGCA and
one TGCGCA sequences ( 545,  456, +505, +1518,
+2204) ﬂank the HBA promoter (not shown).
ChIP experiments with antibodies against VP16 activa-
tion domain showed enrichment over the high aﬃnity
binding site at +801 downstream of RND2 TSS and
+2646 and +2746 downstream of NGFR TSS in cells
transfected with MBD1-VP16 but not in control cells
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Figure 3. MBD1-VP16 fusion activates speciﬁc genes in HeLa cells. (A) The fusion proteins containing DNA binding domains of MBD1, MBD2 and
MeCP2 and transactivation domain of herpes virus (VP16 AD). All proteins have a C-terminal FLAG peptide. (GR)11 is a region of MBD2 rich in glycine
and arginine. (B) Expression of MBD-VP16 fusion proteins in HeLa cells. Histone deacetylase (HDAC1) detected simultaneously with the fusion proteins
serves as a loading control. (C) Expression of MBD1-VP16 and MBD1-VP16 proteins carrying point mutations in either the MBD (R22A) or CXXC3
(K310,319A and C289,292A) domains. MBD1
DM-VP16 combines R22A with C289,292A mutations. HDAC1 serves as a loading control. (D) Log2 plots
show the eﬀect of MBD-VP16 fusion proteins on transcription in HeLa cells. In all graphs the x-axis represents M=log2 MBD-VP16/HeLa and the
y-axis, the control, M=log2 MBD1
DM-VP16/HeLa. Transcripts up-regulated by MBD1-VP16 3-fold or more (M 1.5) are shown in red. Note that
transcripts induced by MBD1-VP16 are not up-regulated after expression of either MBD2-VP16 or MeCP2-VP16.
Nucleic Acids Research, 2010,Vol.38, No. 14 4627transfected with DM-VP16 (Figure 6B and D, left). As
expected, acetylation of histone H3 was high at RND2
and NGFR promoters in MBD1-VP16 transfected cells
but not in the controls (Figure 6B and D, middle).
Moreover, ChIP with antibodies against MBD1 detected
enrichment of the endogenous MBD1 in the same location
as MBD1-VP16 in transfected cells, suggesting that the
fusion protein may compete with the endogenous MBD1
for binding to high aﬃnity sites near RND2 and NGFR
promoters (Figure 6B and D, right). We did not detect
either MBD1 or MBD1-VP16 binding to unmethylated
CpG-rich sequences of RND2 and NGFR promoters
although these, especially in the case of NGFR, would
potentially provide signiﬁcant number of unmethylated
CpGs for binding of CXXC3. Taken together, these ex-
periments indicate that when binding of MBD1-VP16
occurs at methylated CpGs near gene promoters this
leads to histone acetylation and strong expression of
targeted genes.
DNA methylation and MBD1 are required for silencing
of MBD1-VP16 targeted genes
Given that our ChIP experiments detected MBD1 binding
near promoters that were highly induced by MBD1-VP16
transactivator, we wanted to know whether DNA methy-
lation and the endogenous MBD1 are essential for
silencing of these genes. Similar to HeLa cells, HBA and
RND2 are not expressed in the colorectal carcinoma
derived HCT116 cell line, although the CpG islands of
both genes are largely unmethylated (Figure 7A and not
shown). Methylated CpGs can be detected  650bp
upstream and +337bp downstream from the HBA TSS
in HeLa and in HCT116 cells (Figure 7A), but not in
double knock out (DKO) HCT116 cells, which lack
DNMT3B and express a N-terminally truncated
hypomorphic allele of DNMT1 (48–50) (Figure 7A and
not shown). DNA methylation was also absent from the
RND2 promoter in DKO cells compared to the parental
HCT116 cell line (not shown). This is consistent with the
signiﬁcant hypomethylation of the genome observed in
DKO cells (49). Interestingly, HBA and RND2 transcripts
were detectable in DNMT3B null (3B KO) and DKO
cells, suggesting that DNA methylation near these pro-
moters is important for the recruitment of MBD1 and
silencing of HBA and NGFR in HeLa and HCT116
cells (Figure 7B). Consistently, expression of MBD-VP16
proteins in DKO cells did not lead to further activation of
these genes (data not shown).
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Figure 4. Validation of microarray data and characterization of transactivation potential of mutant MBD1-VP16 proteins. (A and B)
Semiquantitative and quantitative RT-PCR experiments demonstrate that transcripts induced by expression of MBD1-VP16 in HeLa by  10-fold
are not up-regulated in cells expressing either MBD2-VP16 or MeCP2-VP16. Actin served as ubiquitously expressed control. The graphs in (B)
represent triplicate RT-qPCRs performed on two independent transfection experiments for each fusion protein. (C and D) Semi-quantitative and
quantitative RT-PCRs show that MBD1-VP16 carrying R22A a mutation in the MBD domain (R22A and DM) is unable to activate target genes
compared to MBD1-VP16 carrying K310,319A mutations in CXXC3. Cysteine mutations (C289A,292A) also abolished transactivation by
MBD1-VP16, presumably by aﬀecting protein folding. Actin was used as a control. RT-qPCR experiments were performed in triplicates on two
independent transfections for each protein. The expression of MBD1-, MBD2- and MeCP2-VP16 fusion proteins as well as expression of mutant
forms of MBD1-VP16 is shown in Figure 3B and C.
4628 Nucleic Acids Research, 2010,Vol.38, No. 14To investigate whether endogenous MBD1 is required
for the repression of genes that are targeted and activated
by MBD1-VP16, we transiently knocked down MBD1
and MBD2 in HeLa cells by a plasmid-driven expression
of a small hairpin (sh) RNAs (Figure 7C and D). Plasmids
carrying a non-silencing shRNAs served as controls. We
did not attempt to knock down MeCP2 as it is expressed
at negligible levels in HeLa cells. MBD1 shRNA reduced
MBD1 RNA and protein levels by  60% compared to the
control cells and led to a partial derepression of HBA,
RND2 and NGFR (Figure 7C and data not shown).
Notably, the expression of these genes in cells with
reduced levels of MBD1 was much weaker that in cells
transfected with MBD1-VP16, which is consistent with
the strong activation properties of the VP16 domain
(Figure 5C and Figure 7C). A comparable knock down
of MBD2 in HeLa did not derepress HBA and NGFR
genes suggesting that MBD2 does not bind at these loci
(Fig 7D). However, we could detect a 2-fold up-regulation
of RND2 in cells stably expressing MBD2 shRNA. Given
that RND2 was not activated by MBD2-VP16 fusion
protein, it is likely that the eﬀect of MBD2 knockdown
on RND2 is indirect.
In summary, these experiments indicate that DNA
methylation and MBD1 protein are required for silencing
of a subset of genes with unmethylated promoters in HeLa
and other cell lines.
DISCUSSION
Despite being viable and fertile, mice null for Mbd1,
Mbd2 and Mecp2 proteins display distinct phenotypes
(16–19,51). Deﬁciency or mutations in Mecp2 in humans
result in a severe neurological disorder known as Rett
syndrome. In Rett patients, as well as in mouse models
of the disease, loss of Mecp2 function mostly aﬀects brain
physiology, as Mecp2 is particularly abundant in mature
postmitotic neurons (18,19,52). Mbd2-null animals show
defects in maternal behaviour and misexpression of genes
in the intestine and in the immune system (17,53–55). In
addition, Mbd2
 /  mouse embryonic ﬁbroblast display
leaky silencing of non-coding RNA Xist resulting in in-
appropriate inactivation of the single active X chromo-
some in a proportion of Mbd2-null male cells (53). The
phenotype of Mbd1-deﬁcient mice is extremely mild.
However, these animals display impaired spatial learning
and defective neurogenesis (16,51). These phenotypes
seem incompatible with high degree of functional redun-
dancy between the MBD family members.
Moreover, investigations in primary human cells have
rarely detected shared occupancy of methylated sites by
MBD family proteins, although this may occur at densely
methylated CpG islands in cancer cell lines (23,26).
Studies aiming to determine DNA-binding preference of
MeCP2 have shown that MeCP2 binds more eﬃciently to
methylated CpG followed by an A/T  4 run (26). The
recently solved crystal structure of the MBD domain of
Mecp2 bound to a sequence derived from the BDNF
promoter, a known target gene for Mecp2, suggests that
the A/T 4 run causes narrowing of the minor groove of
DNA and DNA bending which may stabilize the inter-
action of MBD domain with methylated CpGs (56).
Additionally, the tandem Asx-ST motif in the MBD of
Mecp2, which is not present in Mbd1 or Mbd2, contact
the phosphate backbone at the start of the A/T run (56).
Consistently, we did not detect preferential binding of
MBD domain of Mbd1 to methylated CpGs with an
adjacent A/T run (Supplementary Figure S2B).
In this report we investigate how Mbd1 protein inter-
acts with DNA in vitro and in vivo. We focused on the two
DNA-binding domains of MBD1, the MBD and the
CXXC3, aiming to determine if they bind to DNA in a
sequence-speciﬁc manner. We report for the ﬁrst time that
the MBD domain of MBD1 binds with higher aﬃnity to
speciﬁc methylated sequences in vitro, namely TC
MGCA
and TGC
MGCA. However, the KD of MBD1 MBD
binding to these sequences was only 4–5-fold lower than
the KD measured for the least eﬃcient methylated
sequence CC
MGGC. Furthermore, we also detected selec-
tion for multiple methylated CpGs within the expanded
GCGC sequence in the methyl-SELEX assay. Additional
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Figure 6. Chromatin immunoprecipitation detects MBD1 binding near RND2 and NGFR promoters. (A) Schematic drawing of RND2 promoter with
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4630 Nucleic Acids Research, 2010,Vol.38, No. 14bandshift experiments conﬁrmed that multiple methylated
CpGs can override the sequence preference of MBD1 at
single methylated ones (Supplementary Figure S5).
Therefore, MBD1 as well as MBD2 would be expected
to bind with high aﬃnity to densely methylated CpG
islands. However, in most somatic cells the CpG-rich pro-
moters are not methylated and binding of MBD1 should
mostly occur at single methylated CpGs.
Are the aﬃnities we measured in vitro likely to deter-
mine the patterns of MBD1 binding to methylated DNA
in vivo? Potentially, the occupancy of methylated sites by
MBD1 and other methyl-CpG-binding proteins may
reﬂect the ratio between the total number of available
binding sites and the number of MBD protein molecules
present in the nucleus. Quantitative western blots
indicated that there are  1.2   10
4 molecules of MBD1
per nucleus in HeLa and normal diploid human ﬁbro-
blasts [(15) and data not shown]. Given that on average
there is one CpG/100bp in the bulk genome (excluding
CpG islands) and that  70% of all CpGs are methylated,
the calculated number of methylated CpGs is  2 10
7.
Therefore, the ratio of MBD1 to methylated CpGs is
 1/1670. If only 1% of all methylated CpGs are present
within high aﬃnity MBD1-binding sites, the number of
such sites will be 16-fold higher than the number of
MBD1 molecules in each cell. Therefore, it is likely that
most MBD1 is bound to its preferred binding sites in
HeLa, provided that they are not obstructed by nucleo-
somes or other DNA bound proteins.
On the other hand, we found that the CXXC3 zinc
ﬁnger of MBD1 has no sequence speciﬁcity and can
bind in vitro to a single unmethylated CG within any
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Figure 7. DNA methylation and endogenous MBD1 are required for silencing of HBA and RND2 genes. (A) Schematic representation of HBA
promoter. DNA methylation of the region from  797 to +662 was analysed by bisulphite sequencing. The average methylation patterns in HeLa,
HCT116 and HCT116 DNMT3B KO/DNMT1 hypomorph cells (D3/D1 DKO) are shown. (B) Semi-quantitative RT-PCRs detect HBA and RND2
transcripts in DNMT-deﬁcient but not in wild-type HCT116 cells. (C) Quantitative RT-PCRs detect derepression of HBA, RND2 and NGFR genes
relative to the GAPDH control after a partial 60% knock down of MBD1 in HeLa cells by shRNA. A vector carrying non-silencing shRNA
sequence directed against MBD1 served as a negative control. (D) Comparable knock down of MBD2 by shRNA in HeLa cells has no eﬀect on
silencing of HBA and NGFR, but results in some derepression of RND2. A vector carrying non-silencing shRNA sequence directed against MBD2
served as a negative control.
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domain led to enrichment for additional CG dinucleotides
but not CXXC3-speciﬁc sequence motifs (data not
shown). This is consistent with recent ﬁndings that
CXXC3 domain of MBD1 can be used to purify
CpG-islands from fragmented genomic DNA (4).
However, we failed to detect binding of CXXC3 to
unmethylated CpG island promoters in vivo.
MBD1
K310,319A-VP16 mutant deﬁcient in binding to
unmethylated CpGs could activate target genes as eﬃ-
ciently as the ‘wild-type’ MBD1-VP16 and neither the en-
dogenous MBD1 nor the exogenous MBD1-VP16 were
enriched at CpG island promoters of NGFR and RND2
genes. This indicates that the unmethylated CpG-rich pro-
moters are somehow protected against binding of MBD1
presumably by other proteins that may compete with
MBD1. In contrast, the R22A mutation in the MBD
domain, which abolishes binding to methylated DNA
in vitro, signiﬁcantly reduced the transactivation activity
of MBD1
R22A-VP16 at all genes that we analysed. Taken
together, these data demonstrate that the MBD and the
CXXC3 domains do not contribute equally to stable
binding of MBD1 to DNA in vivo and indicate the
dominant role of the MBD domain and DNA methylation
in determining the patterns of MBD1 distribution
throughout the genome.
The physiological function of CXXC3 in vivo is yet to be
determined. It is possible that this domain is functional
only when the levels of DNA methylation in the genome
are signiﬁcantly reduced, for example in preimplantation
mouse embryos (1,57). This is consistent with earlier ob-
servations that in the presence of non-functional MBD
domain CXXC3 can support binding of MBD1 at major
satellite DNA in Dnmt1
 /  mouse embryonic ﬁbroblasts
but not in ‘wild-type’ cells (31).
Although the transactivation assays provide a useful
tool to study the contribution of DNA-binding domains
of MBD1 to targeting speciﬁc genes in vivo, it is important
to acknowledge that the microarray experiments identiﬁed
only a small number of signiﬁcantly ( 3-fold)
up-regulated genes by MBD1-VP16 in any of the
examined cell lines. One may wonder why the number of
‘activatable’ promoters is small and whether they share
any common features. Notably, all the 34 genes identiﬁed
as MBD1 targets in HeLa contain 1–4 either TGCGCA or
TCGCA sites in close proximity to the promoter.
However, since a limited number of MBD1-VP16
activated genes are available for analysis, any features
found at these promoters may not withstand rigorous stat-
istical tests when compared to the rest of the promoters in
the genome. In fact   33% (7743) of all protein coding
genes contain one or more MBD1-prefered-binding se-
quences within a 1kb region ﬂanking TSS (from  500
to +500bp). These promoters would be potential targets
for MBD1 if methylated. As 82% of them are CpG islands
and the majority of these are not methylated in any given
cell type, this would reduce signiﬁcantly the number of
potential target genes. On the other hand, TC
MGCA
and TGC
MGCA sequences are relatively
underrepresented in the rest of the genome (on average
one site/ 5kb). As the promoters of genes which we
examined in detail were not methylated, but binding of
MBD1 was detectable at TC
MGCA sites in the proximity
of their CpG-islands, this may indicate that our transac-
tivation assay was biased towards identiﬁcation of genes,
at which binding of MBD1 occurs suﬃciently close to the
promoter to allow activation. Further experiments
designed to map binding of endogenous MBD1 in
mammalian cells in comparison to DNA methylation
patterns will be needed to fully understand how MBD1
functions in vivo.
In summary, we found that MBD1 binds more eﬃcient-
ly to a single methylated CpG in the context of TC
MGCA
and TGC
MGCA sites in vitro and in vivo. We identiﬁed
speciﬁc genes targeted for silencing by MBD1 in several
human cell lines and demonstrated that recruitment of
MBD1-VP16 transactivator to these loci occurs due to
the preference of the MBD domain for methylated DNA
in speciﬁc sequence context. Most importantly, other
MBD domains did not display high aﬃnity for
MBD1-binding sites and were not recruited to the same
genes when expressed as MBD-VP16 fusion proteins.
Taken together with the sequence preference of MeCP2
(26), our data suggest that silencing by MBD1 and
MeCP2 is restricted to subsets of genes that harbour
methylated sequences supporting stable binding of these
proteins to DNA.
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